In-Hospital Mortality and Costs of Added Morbidity in Heart Failure Patients at a University Hospital: A Retrospective Cross-Sectional Study
Authors:
- Lourdes Raya OrtegaLOLourdes Raya Ortega
- Jesús Martínez TapiasJTJesús Martínez Tapias
- María José Ferreras FernándezMFMaría José Ferreras Fernández
- Manuel Jiménez-NavarroMJManuel Jiménez-Navarro
- Almudena Ortega-GómezAOAlmudena Ortega-Gómez
- Miguel Romero-CuevasMiguel Romero-Cuevas
- Juan José Gómez-DoblasJGJuan José Gómez-Doblas
Open Access
- 15 May 2025
- journal article
- research article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (5) , 185
Abstract
Background: Heart failure (HF) is a leading cause of hospital admissions and in-hospital mortality among the elderly. This study aims to characterize HF patients admitted to Virgen de la Victoria University Hospital (HUVV), identify factors associated with in-hospital mortality and analyze the impact of added morbidity on healthcare costs. Methods: A cross-sectional study was conducted using data from the Minimum Basic Data Set (MBDS) at HUVV. We included all discharges with a primary diagnosis of HF in 2021. Logistic regression analysis was employed to identify factors associated with mortality, and cost analysis was performed to assess the economic impact of added morbidity. Results: A total of 731 hospital discharges for HF were analyzed, with a mortality rate of 14.77%. Mortality was significantly associated with age ≥ 75 years (OR = 4.12; p < 0.001), high or extreme severity (OR = 2.26 and 8.10, respectively; p < 0.001), and more than 10 diagnoses at discharge (OR = 2.95; p < 0.01). Treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) was associated with a reduced risk of death (OR = 0.29; p < 0.001). Hospital-acquired morbidity occurred in 27.22% of patients, resulting in an additional cost of EUR 152,780.61, representing a 3.8% increase over the total hospitalization costs. Conclusions: In-hospital mortality in HF patients at HUVV is strongly associated with advanced age, disease severity, and multiple comorbidities. Treatment with ACEIs or ARBs was associated with a lower likelihood of in-hospital mortality. Preventable added morbidity was associated with increased healthcare costs, highlighting the importance of infection control measures and multidisciplinary management to potentially improve outcomes and reduce costs.Keywords
Funding Information
- Instituto de Salud Carlos III (ISCIII) (CP20/0060)
This publication has 32 references indexed in Scilit:
- Effects of sacubitril/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniquesBiomedicine & Pharmacotherapy, 2025
- Características clínicas, manejo y riesgo de complicaciones a un año en pacientes con insuficiencia cardíaca con y sin diabetes tipo 2 en EspañaRevista Clínica Española, 2022
- Mortalidad hospitalaria y reingresos por insuficiencia cardiaca en España. Un estudio de los episodios índice y los reingresos por causas cardiacas a los 30 días y al añoRevista Espanola de Cardiologia, 2019
- National Trends in Healthcare-Associated Infections for Five Common Cardiovascular ConditionsThe American Journal of Cardiology, 2019
- Primera hospitalización por insuficiencia cardiaca: mortalidad hospitalaria y perfil del pacienteRevista Clínica Española, 2018
- Tratamiento farmacológico en la insuficiencia cardiaca agudaRevista Espanola de Cardiologia, 2015
- Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca crónica sintomática en EspañaRevista Espanola de Cardiologia, 2014
- Epidemiología de la insuficiencia cardiaca en España en los últimos 20 añosRevista Espanola de Cardiologia, 2013
- Factores pronósticos y supervivencia a largo plazo tras el diagnóstico inicial de insuficiencia cardiacaMedicina Clinica, 2012
- Benefit of specialized clinics for the treatment of patients with heart failureEuropean Journal of Internal Medicine, 2011